Related Experiment Video
Updated: May 28, 2026
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Adjuvant effect of a natural TLR4 ligand on dendritic cell-based cancer immunotherapy
Jee Youn Kim1, Yeon Jin Kim, Ji Sung Kim
1College of Pharmacy and Medical Research Center (CICT), Chungbuk National University, Cheongju, Chungbuk, Republic of Korea.
Abstract:
The clinical efficacy of dendritic cell (DC) vaccine in cancer patients has been unsatisfactory due, at least in part, to the deficiency of maturation and impaired migration of ex vivo generated DCs to the draining lymph nodes. To solve this problem, we used angelan, a natural TLR4 ligand, to enhance the maturation and migration of DCs. Angelan increased the expression of MHC-I/II, CD80, and CD86, DC maturation markers, through the NF-κB pathway. This compound also increased CCR7 expression in DCs through NF-κB and p38 pathway and enhanced their migration against CCL19, which is a key chemokine that guides DCs into lymph nodes. We also showed that angelan enhanced in vivo DC homing from tissues to draining lymph nodes. When treated to DCs in vitro and vivo, angelan increased antitumor activity of DCs in B16F10 syngeneic tumor model. Taken together, the present data suggest that a natural TLR4 ligand might be helpful for overcoming the disadvantages of DC-based cancer therapy, such as impaired maturation and poor migration in cancer patients.
Insights
Angelan, a natural TLR4 ligand, enhances dendritic cell (DC) maturation and migration. This improves DC-based cancer therapy by boosting antitumor activity and overcoming common limitations in cancer patients.
Area of Science:
- Immunology
- Cancer Biology
- Pharmacology
Background:
- Clinical efficacy of dendritic cell (DC) vaccines is limited by poor DC maturation and migration.
- Ex vivo generated DCs often fail to reach draining lymph nodes effectively.
- Existing cancer therapies require novel strategies to enhance DC vaccine performance.
Purpose of the Study:
- To investigate angelan, a natural TLR4 ligand, as a means to improve DC maturation and migration.
- To evaluate the impact of angelan on DC homing and antitumor activity.
- To address the limitations of DC-based cancer immunotherapy.
Main Methods:
- Utilized angelan, a natural TLR4 ligand, to treat DCs ex vivo and in vivo.
- Assessed DC maturation markers (MHC-I/II, CD80, CD86) and CCR7 expression.
- Investigated the role of NF-κB and p38 pathways in angelan-mediated effects.
- Evaluated DC migration towards CCL19 and in vivo homing to lymph nodes.
- Tested the efficacy of angelan-treated DCs in a B16F10 syngeneic tumor model.
Main Results:
- Angelan significantly upregulated DC maturation markers (MHC-I/II, CD80, CD86) via the NF-κB pathway.
- Angelan increased CCR7 expression through NF-κB and p38 pathways, enhancing DC migration.
- Angelan improved in vivo DC homing to draining lymph nodes.
- Treatment with angelan-boosted DCs demonstrated enhanced antitumor activity in a preclinical cancer model.
Conclusions:
- Angelan effectively enhances both the maturation and migration of dendritic cells.
- This natural TLR4 ligand shows promise in overcoming critical barriers in DC-based cancer therapy.
- Angelan represents a potential therapeutic strategy to improve the clinical outcomes of cancer immunotherapy.
